Pharmaceutical

MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine

The UK MHRA has authorised Pfizer-BioNTech’s adapted Comirnaty vaccine against the JN.1 Covid-19 subvariant for adults and children.

Jul 26, 2024 - 04:00
MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
The UK MHRA has authorised Pfizer-BioNTech’s adapted Comirnaty vaccine against the JN.1 Covid-19 subvariant for adults and children.
Read the original article

Tags:

Previous Article

Dren Bio and Novartis link on bispecific antibodies for cancer

Next Article

BioAtla receives FDA fast track designation for ozuriftamab vedotin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug

STAT+: Neurocrine reports second late-stage trial succe...

Oct 6, 2023

2023 Nobel Prize in chemistry: Trio win for quantum dots discoveries that revolutionized nanotechnology

2023 Nobel Prize in chemistry: Trio win for quantum dot...

Oct 4, 2023

Generalized Pustular Psoriasis (GPP) drugs in developme...

Aug 31, 2024